In this video, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses preclinical data on vorolanib ...
Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...
High-resolution microscopic images of T cells that have been engineered with TGF-beta SNIPRs (shown in red) as they bind to TGF-beta (shown in green). The SNIPRs activate once the receptors fold into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback